Peps
What is Abaloparatide?
Abaloparatide is a bone-forming prescription medicine for osteoporosis. Its clinically relevant outcome is prevention of fractures in appropriately selected patients.
Biological role or research focus
Bone formation in osteoporosis care.
Its clinical context is selected patients at high fracture risk, not general joint repair.
Role reference: MedlinePlus · Abaloparatide ↗
Names you may encounter
Tymlos
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- PTH1 receptor agonist
- Main research area
- Bone formation
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Abaloparatide ↗
Molecular structure
Mechanism & research rationale
It activates the parathyroid-hormone type 1 receptor. The therapeutic aim is increased bone formation and strength; this is a different biological question from repairing tendons or cartilage.
Source: MedlinePlus · Abaloparatide ↗
Clinical uses & product context
The medication reference describes osteoporosis care. Treatment selection depends on fracture risk, previous therapies, and the exact product label. A bone-density change is useful, but fracture outcomes provide the more direct clinical test.
Source: MedlinePlus · Abaloparatide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2016
ACTIVE
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
- Population / model
- 2,463 postmenopausal women with osteoporosis.
- Study design
- 18 months; blinded abaloparatide versus placebo, with an open-label teriparatide arm.
- Main finding
- New vertebral and nonvertebral fractures were less frequent with abaloparatide than placebo, and bone mineral density increased. Hypercalcemia occurred in 3.4% with abaloparatide versus 6.4% with teriparatide.
- Limits & context
- The trial addresses fracture prevention in osteoporosis. The open-label comparator and selected population limit claims of universal superiority or benefit for healthy athletes.
Human trial extension · 2018
ACTIVExtend · sequential treatment
Were fracture benefits maintained after switching to another medicine?
- Population / model
- 558 prior abaloparatide recipients and 581 prior placebo recipients who completed ACTIVE.
- Study design
- Both groups received alendronate for up to 24 months; outcomes were measured across the original trial and extension.
- Main finding
- Across 43 months, new radiographic vertebral fractures occurred in 0.9% versus 5.6% of evaluable women, favoring the abaloparatide-to-alendronate sequence.
- How to read it
- The absolute difference was 4.7 percentage points. The reported 84% relative reduction is a different measure.
- Limits & context
- Completer selection and sequential alendronate treatment limit attribution. This is not evidence for uninterrupted abaloparatide, general bone repair, or outcomes in healthy people.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 3 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Osteoporosis: A Review. ↗
JAMA · 2025 Sep 9 · Journal Article, Review
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. ↗
Archives of osteoporosis · 2025 Sep 8 · Journal Article, Practice Guideline
Read available full text ↗
Recent Advances in Osteoporosis Therapeutics. ↗
Annual review of medicine · 2026 Jan · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Dizziness, nausea, palpitations, and increased calcium are relevant concerns. Kidney stones and conditions associated with greater osteosarcoma risk require clinical review; the animal tumor finding should not be described as proven human causation.
Source: MedlinePlus · Abaloparatide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its clinical context is selected patients at high fracture risk, not general joint repair.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is stronger bone the same as joint repair?
No. Osteoporosis trials measure bone density and fractures. Those findings do not establish cartilage regeneration or tendon recovery.
Source: MedlinePlus · Abaloparatide ↗
Was it proven better than every alternative?
No. ACTIVE included an open-label teriparatide arm, but it does not provide a universal ranking across osteoporosis treatments.
References & editorial record
- MedlinePlus · Abaloparatide ↗
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. ↗
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.